Vestmark Advisory Solutions Inc. Buys 45,068 Shares of Relx Plc $RELX

Key Points

• Vestmark Advisory Solutions Inc. has increased its holdings in Relx Plc by 107.6%, owning 86,940 shares valued at approximately $4.38 million.
• Relx recently declared a semi-annual dividend of $0.2634 per share, which reflects a significant dividend yield of 170.0%, with a payout ratio of 27.96%.
• Analysts have upgraded Relx's rating from a "hold" to a "buy", with a consensus rating of "Buy" supported by five analysts, indicating positive market sentiment towards the stock.

Vestmark Advisory Solutions Inc. grew its holdings in shares of Relx Plc (NYSE:RELX - Free Report) by 107.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 86,940 shares of the technology company's stock after purchasing an additional 45,068 shares during the quarter. Vestmark Advisory Solutions Inc.'s holdings in Relx were worth $4,383,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of RELX. Ameriprise Financial Inc. raised its stake in Relx by 368.7% in the fourth quarter. Ameriprise Financial Inc. now owns 2,807,038 shares of the technology company's stock valued at $127,437,000 after purchasing an additional 2,208,119 shares in the last quarter. Northern Trust Corp increased its position in Relx by 51.6% during the 4th quarter. Northern Trust Corp now owns 2,191,588 shares of the technology company's stock valued at $99,542,000 after purchasing an additional 745,532 shares during the period. GAMMA Investing LLC increased its position in Relx by 6,125.5% during the 1st quarter. GAMMA Investing LLC now owns 679,073 shares of the technology company's stock valued at $34,232,000 after purchasing an additional 668,165 shares during the period. Carnegie Investment Counsel purchased a new position in Relx during the 1st quarter valued at $16,026,000. Finally, Bank of America Corp DE increased its position in Relx by 4.2% during the 4th quarter. Bank of America Corp DE now owns 6,246,462 shares of the technology company's stock valued at $283,714,000 after purchasing an additional 253,107 shares during the period. 15.02% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Relx from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy".

Relx Stock Performance

NYSE RELX traded down $0.5350 during trading on Thursday, reaching $48.1550. 399,127 shares of the company's stock were exchanged, compared to its average volume of 864,854. Relx Plc has a fifty-two week low of $44.19 and a fifty-two week high of $56.33. The stock has a market capitalization of $88.34 billion, a P/E ratio of 25.91, a PEG ratio of 3.12 and a beta of 0.88. The business has a 50 day moving average price of $51.88 and a 200-day moving average price of $51.51. The company has a debt-to-equity ratio of 2.55, a current ratio of 0.47 and a quick ratio of 0.42.

Relx Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, September 16th. Stockholders of record on Friday, August 8th will be issued a dividend of $0.2634 per share. The ex-dividend date is Friday, August 8th. This represents a dividend yield of 170.0%. Relx's dividend payout ratio is 28.49%.

Relx Company Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.